History & Milestones

1952

Founded as China Chemical & Pharmaceutical Co., Ltd. (CCPC)

1959

Entered technical collaboration with U.S. firm E.R. Squibb (now Bristol Myers Squibb)

1960

Completed construction of research and testing facility at original Shulin plant

1962

Became Taiwan's first publicly listed pharmaceutical company

1964

First Taiwan-based manufacturer to receive U.S. FDA certification

1970

Co-founded Sino-Japan Chemical Co., Ltd with Daiichi Sankyo

1976–1978

First in Taiwan to implement WHO-aligned GMP; expanded R&D and manufacturing capabilities through partnering with global firms including Syntex Laboratories (later acquired by Roche)

1985–1989

Signed major licensing deals with Japanese partners such as Ono Pharmaceutical; established the Wang Ming-Ning Foundation to support medical research in Taiwan

1993

Established Suzhou Cenra (formerly CCPC Suzhou), among the first in China to receive GMP certification

1997

Completed Hsinfeng plant—Taiwan’s first facility to meet cGMP standards

2000–2001

Received multiple national awards for manufacturing and healthcare quality excellence from Taiwan’s MOHW, MOEA, and IBMI

2004

Spun off Cenra Healthcare (formerly Chunghwa Yuming) to lead commercialization and business development

2005-2006

Acquired Sankyo’s (now Daiichi Sankyo) Tainan plant; launched senior care joint venture with U.S.-based Home Instead

2010s

Began initial contract development and manufacturing (CDMO) engagements for external clients

2013

Tainan Plant II passed U.S. FDA (PIC/S) inspection

2015

Hsinfeng and Taichung plants passed Japan PMDA audits

2015

Senior care division rebranded as Chunghwa Senior Care (now Cenra Senior Care)

2019

Oncology line at Hsinfeng plant certified by Taiwan TFDA under PICS/GMP standards

2024

Established Cenra Inc. as the holding company
The name “Cenra” blends the English “center” and the Latin “cura” —symbolizing care at the core.

Launched renewed phase of focus: from legacy pharma to platform-based healthcare enterprise with strategic pillars in Prescription (Rx) medicines, contract development & manufacturing (CDMO), consumer healthcare, senior care services, and international partnerships.